益佰制药
(600594)
| 流通市值:24.32亿 | | | 总市值:24.32亿 |
| 流通股本:7.84亿 | | | 总股本:7.84亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 989,980,001.03 | 689,387,704.62 | 358,837,040.95 | 1,862,920,853.13 |
| 营业收入 | 989,980,001.03 | 689,387,704.62 | 358,837,040.95 | 1,862,920,853.13 |
| 二、营业总成本 | 1,110,706,131.69 | 742,482,846.67 | 374,652,779.96 | 2,001,366,895.95 |
| 营业成本 | 453,179,641.15 | 291,849,727.86 | 150,985,925.19 | 751,460,808.48 |
| 税金及附加 | 21,185,710.85 | 14,456,229.86 | 8,511,918.69 | 31,457,220.29 |
| 销售费用 | 381,877,248.46 | 270,860,570.2 | 137,626,547.14 | 822,931,542.08 |
| 管理费用 | 198,379,278.97 | 123,090,573.77 | 58,623,429.15 | 290,532,433.13 |
| 研发费用 | 40,229,637.51 | 31,516,868.25 | 13,469,997.18 | 84,269,082.59 |
| 财务费用 | 15,854,614.75 | 10,708,876.73 | 5,434,962.61 | 20,715,809.38 |
| 其中:利息费用 | 16,866,612.75 | 11,382,355.03 | 5,691,450.14 | 23,374,518.45 |
| 其中:利息收入 | 1,605,391.54 | 1,068,361.22 | 485,260.48 | 3,767,249.28 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 46,795.14 | -80,051.75 | -5,196.72 | -214,599.61 |
| 资产处置收益 | 1,774,022.19 | 1,827,269.37 | 1,836,628.72 | -27,210,380.43 |
| 资产减值损失(新) | -34,815,168.83 | -30,578,373.02 | -12,212,528.62 | -159,485,265.14 |
| 信用减值损失(新) | 288,333.69 | 288,333.69 | 47,826.78 | -2,794,771.52 |
| 其他收益 | 11,294,956.49 | 7,451,488.12 | 4,244,601.78 | 24,168,885.77 |
| 四、营业利润 | -142,137,191.98 | -74,186,475.64 | -21,904,407.07 | -303,982,173.75 |
| 加:营业外收入 | 4,293,295.34 | 3,011,527.74 | 1,363,626.27 | 4,710,784.35 |
| 减:营业外支出 | 3,591,213.77 | 1,897,716.12 | 334,699.8 | 12,476,946.3 |
| 五、利润总额 | -141,435,110.41 | -73,072,664.02 | -20,875,480.6 | -311,748,335.7 |
| 减:所得税费用 | 6,802,353.39 | 5,387,915.87 | 8,087,807.44 | 23,593,549.41 |
| 六、净利润 | -148,237,463.8 | -78,460,579.89 | -28,963,288.04 | -335,341,885.11 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -148,237,463.8 | -78,460,579.89 | -28,963,288.04 | -335,341,885.11 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -151,250,491.81 | -80,337,813.1 | -29,524,902.89 | -329,562,325.95 |
| 少数股东损益 | 3,013,028.01 | 1,877,233.21 | 561,614.85 | -5,779,559.16 |
| 扣除非经常损益后的净利润 | -162,517,142.91 | -87,454,282.99 | -34,801,324.57 | -325,096,335.78 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.19 | -0.1 | -0.04 | -0.42 |
| (二)稀释每股收益 | -0.19 | -0.1 | -0.04 | -0.42 |
| 八、其他综合收益 | -5,227.4 | 7,181.75 | - | -164,440.9 |
| 归属于母公司股东的其他综合收益 | -5,227.4 | 7,181.75 | - | -164,440.9 |
| 九、综合收益总额 | -148,242,691.2 | -78,453,398.14 | -28,963,288.04 | -335,506,326.01 |
| 归属于母公司股东的综合收益总额 | -151,255,719.21 | -80,330,631.35 | -29,524,902.89 | -329,726,766.85 |
| 归属于少数股东的综合收益总额 | 3,013,028.01 | 1,877,233.21 | 561,614.85 | -5,779,559.16 |
| 公告日期 | 2026-10-31 | 2026-08-21 | 2026-04-23 | 2026-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |